{"id":504509,"date":"2020-08-27T17:44:02","date_gmt":"2020-08-27T17:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=504509"},"modified":"2020-08-27T17:44:02","modified_gmt":"2020-08-27T17:44:02","slug":"vernal-keratoconjunctivitis-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-epidemiology-forecast-till-2030_504509.html","title":{"rendered":"Vernal Keratoconjunctivitis Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vernal Keratoconjunctivitis Epidemiology Forecast till 2030  \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Vernal Keratoconjunctivitis Epidemiology Forecast till 2030  \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8216;Vernal Keratoconjunctivitis &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and\/or upper tarsal giant conjunctival papillae.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-epidemiology-forecast\" target=\"_blank\"><strong>Vernal Keratoconjunctivitis Epidemiology Segmentation in Total Major Market from 2017 to 2030<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent Population of Vernal Keratoconjunctivitis<\/li>\n<li>Total Diagnosed Prevalent Cases of VKC<\/li>\n<li>Gender-specific Diagnosed Prevalent Cases of VKC<\/li>\n<li>Type-specific Diagnosed Prevalent Cases of VKC<\/li>\n<li>Severity-specific Diagnosed Prevalent Cases of VKC<\/li>\n<li>Age-specific Diagnosed Prevalent Cases of VKC<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-epidemiology-forecast\" target=\"_blank\"><strong>Vernal Keratoconjunctivitis Epidemiology Insights<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total prevalent population of Vernal Keratoconjunctivitis in the total market (7MM, China, Egypt, Saudi Arabia and Russia) in 2017&nbsp; was 4,752,356<\/li>\n<li>The prevalence of VKC in the United States in 2017 was&nbsp; 65,309<\/li>\n<li>Among the EU-5 countries, the prevalent population of VKC in 2017 in Italy was 172,591 whereas in Spain, it was 15,645.&nbsp;<\/li>\n<li>The diagnosed prevalence was higher for males as compared to females in all the total major markets countries<\/li>\n<li>China contributes the largest share in 2017 was 2,248,706<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Vernal Keratoconjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Vernal Keratoconjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Vernal Keratoconjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Vernal Keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Vernal Keratoconjunctivitis<\/li>\n<li>The report provides the segmentation of the Vernal Keratoconjunctivitis epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-epidemiology-forecast\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-epidemiology-forecast\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Vernal keratoconjunctivitis (VKC)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Vernal keratoconjunctivitis (VKC): Epidemiology Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Total Epidemiological Share (%) Distribution of VKC in 2017<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.2. Total Epidemiological Share (%) Distribution of VKC in 2030<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.2. Signs and Symptoms of VKC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.2.1.&nbsp;Signs<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.3. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.4. Risk Factors<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.5. Grades of VKC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.6. Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>4.6.1.&nbsp;Mediators in VKC<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>4.6.2.&nbsp;Cells in VKC<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.7. Histopathology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.8. Diagnosis of VKC<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. Case Reports<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Vernal Keratoconjunctivitis: A Teaching Case Report<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2. Ocular surface disease: A case of vernal keratoconjunctivitis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.1. Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.2. Epidemiology Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. United States Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. EU5 Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.2. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.1.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.2.&nbsp;Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.3.&nbsp;Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.4.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.5.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.2.6.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.3. France Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.1.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.2.&nbsp;Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.3.&nbsp;Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.4.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.5.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.3.6.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.4. Italy Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.1.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.2.&nbsp;Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.3.&nbsp;Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.4.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.5.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.4.6.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.5. Spain Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.1.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.2.&nbsp;Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.3.&nbsp;Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.4.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.5.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.5.6.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.6. United Kingdom Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.1.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.2.&nbsp;Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.3.&nbsp;Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.4.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.5.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>8.6.6.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.1.&nbsp;Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.2.&nbsp;Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.3.&nbsp;Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.4.&nbsp;Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.5.&nbsp;Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.6.&nbsp;Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.7.&nbsp;Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. MEA Region Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.2.Saudi Arabia Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.3.Egypt Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.4.UAE Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>10.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. China Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Russia Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>14.1. Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>14.2. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vernal-keratoconjunctivitis-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vernal-keratoconjunctivitis-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Vernal Keratoconjunctivitis &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-epidemiology-forecast-till-2030_504509.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-504509","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=504509"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=504509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=504509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=504509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}